SecBot SecBot

PMN drug pipeline

$3.31
+0.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 1b
Time to marketYears away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.

PMN310 Updated Jul 14

What to watch

The Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).

Bull case
  • Selective oligomer-targeting mechanism is differentiated from approved plaque-directed antibodies (lecanemab, donanemab); may reduce ARIA brain-swelling risk, a major safety limitation of existing drugs
  • Phase 1a data demonstrated dose-dependent BBB penetration and first-in-human evidence of Aβ oligomer reduction in CSF (presented at AAIC July 2026), a pharmacodynamic proof-of-mechanism no competitor has shown at this stage
  • PRECISE-AD 144 patients exceeds original 128-patient target, suggesting enthusiasm from patients and physicians; 3 dose levels vs. placebo with 12-month treatment and comprehensive biomarker panel (pTau217, pTau243, synaptic markers)
Bear case
  • Phase 1b is still an early-stage safety/biomarker trial, no efficacy conclusions can be drawn; the blinded interim is not a pivotal readout. The stock could sell off on any cautious language even if data is neutral
  • Alzheimer's is an intensely competitive field: lecanemab (Eisai/Biogen) and donanemab (Lilly) are already approved. Acumen's sabirnetug, another oligomer-selective antibody, is in Phase 2 with topline due late 2026 and could beat PMN310 to market
  • No revenue, no approved products, and heavy cash burn (FY2026 EPS est. -$8.24). The company is entirely reliant on PMN310, any setback would be existential